Goal-Directed Fluid Therapy Enhances Gastrointestinal Recovery after Laparoscopic Surgery: A Systematic Review and Meta-Analysis

Marcell Virág 1,2,3, Máté Rottler 1,2,3, Noémi Gede 1, Klementina Ocskay 1,4, Tamás Leiner 1,5, Máté Tuba 1, Szabolcs Ábrahám 1, Nelli Farkas 1, Péter Hegyi 1,4,6 and Zsolt Molnár 1,3,4,7,8,*

Abstract: (1) Background: Whether goal-directed fluid therapy (GDFT) provides any outcome benefit as compared to non-goal-directed fluid therapy (N-GDFT) in elective abdominal laparoscopic surgery has not been determined yet. (2) Methods: A systematic literature search was conducted in MEDLINE, Embase, CENTRAL, Web of Science, and Scopus. The main outcomes were length of hospital stay (LOHS), time to first flatus and stool, intraoperative fluid and vasopressor requirements, serum lactate levels, and urinary output. Pooled risks ratios (RRs) with 95% confidence intervals (CI) were calculated for dichotomous outcomes and weighted mean difference (WMD) with 95% CI for continuous outcomes. (3) Results: Eleven studies were included in the quantitative, and fifteen in the qualitative synthesis. LOHS (WMD: −1.18 days, 95% CI: −1.84 to −0.53) and time to first stool (WMD: −9.8 h; CI −12.7 to −7.0) were significantly shorter in the GDFT group. GDFT resulted in significantly less intraoperative fluid administration (WMD: −441 mL, 95% CI: −790 to −2) and lower lactate levels at the end of the operation: WMD: −0.53 mmol L−1; 95% CI: −0.36 to −0.14. (4) Conclusions: GDFT resulted in enhanced recovery of the gastrointestinal function and shorter LOHS as compared to N-GDFT.

Keywords: enhanced recovery after surgery; goal-directed fluid therapy; intraoperative fluid management; haemodynamic monitoring; laparoscopic abdominal surgery; perioperative care

1. Introduction

Laparoscopic surgical techniques have become the first choice over the last decade due to the lower incidence of postoperative surgical complications, faster recovery, and less postoperative pain compared to the traditional open techniques [1]. Although the surgical trauma is substantially less with laparoscopic than with open surgery [2,3], the increased intraabdominal pressure caused by the insufflation of the peritoneum can lead to hemodynamic instability, resulting in unfavourable neuroendocrine responses and outcomes [4,5].
Furthermore, laparoscopic surgery may lengthen procedural time compared to laparotomy, which can also pose a special challenge during the anaesthetic management [6].

It is well known that inappropriate intraoperative fluid administration as part of hemodynamic management increases the rates of postoperative complications, could delay the recovery of gastrointestinal function, and therefore may lead to prolonged length of hospital stay [7]. The Early Recovery After Surgery (ERAS) Society highlights the importance of fluid management in its guidelines. Inadequate and/or uncontrolled fluid administration can lead to unnecessary fluid restriction or fluid overload [8–10]. The elevated intraabdominal pressure and Trendelenburg and reverse Trendelenburg positions during laparoscopic surgery may reduce renal and splanchnic blood flow [11,12]. This phenomenon is potentially escalated by inadequate intraoperative fluid administration, especially in vulnerable patients suffering from chronic cardiovascular diseases and obesity [13,14].

Defining the appropriate amount of fluid for an individual patient is not easy. One of the potential alternatives is goal-directed fluid therapy (GDFT) [15]. The beneficial effects of GDFT on postoperative complications in high-risk surgical patients have been shown in previous meta-analyses [16,17]. However, a recent randomised clinical trial was unable to demonstrate the clinical benefit of GDFT in elective colectomy patients managed according to the ERAS guideline [18]. Therefore, which patients would benefit from GDFT within the context of the ERAS concept remains unclear [19].

The recent meta-analyses assessing GDF and N-GDF [20–28] and the guidelines for intraoperative fluid therapy of ERAS and the American Society for Enhanced Recovery do not contain clear recommendations for fluid therapy in laparoscopic surgery [29–31]. Therefore, we decided to conduct a systematic review and meta-analysis to assess the effects of GDFT on several postoperative outcomes in patients undergoing elective laparoscopic abdominal surgery.

2. Materials and Methods

2.1. Registration and Protocol

Our systematic review and meta-analysis were reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [32]. The study protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO) in January 2021 (CRD42021230286). After gathering the statistical results for urinary output and operation time, we considered it feasible to standardise the intraoperative urinary output to the length of the operation, which gave more adequate information about the diuresis per hour of the patients, and thus we decided to deviate from the previously registered protocol in this particular case. There were no other deviations.

2.2. Eligibility Criteria

Goal-directed fluid therapy (GDFT) versus non-goal-directed fluid therapy (N-GDFT) was compared in adults undergoing abdominal laparoscopic surgery. Only randomised controlled trials (RCTs) were eligible for inclusion. GDFT was defined as the protocolised administration of fluids and vasoactive and inotropic agents on the basis of haemodynamic assessment, targeted to reach the therapeutic goals [33]. A list of accepted haemodynamic measurement devices is shown in Table S1. Central venous pressure (CVP)-guided fluid therapy was not considered as GDFT [34]. All laparoscopic abdominal, urological, and gynaecological surgical interventions were included in the analysis, except for laparoscopic cholecystectomy, where we did not consider the application of advanced haemodynamic monitoring feasible due to the short operation times. RCTs reporting data for laparoscopic subgroups separately were also accepted.

2.3. Data Items

The following outcomes were evaluated: length of hospital stay (days) defined as the time elapsed between the admission and discharge of the patients, 30-day readmission rate (percentage), reoperation rate (percentage), overall complications (number of patients with
at least one undesired event defined by the individual study) within 30 days, appearance of the time to first flatus and first stool after the intervention (hours), intraoperatively administered fluids (mL), number of patients receiving any vasoactive agents during the intraoperative period, urinary output standardised to the length of surgery (mL h\(^{-1}\)), and serum lactate level at the end of the operation (mmol L\(^{-1}\)).

2.4. Search Strategy and Information Sources

A systematic search was conducted in MedLine via PUBMED\(^\circledR\), Embase\(^\circledR\), Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, and SCOPUS\(^\circledR\) without any language restrictions and date filters. The last search took place on the 16th of December 2021. Our search key is included in Table S2.

2.5. Selection Process

Duplicates were removed by using a reference management software (EndNote X9, Clarivate Analytics). Title and abstract, and finally the full-text selection were conducted independently by two of the authors (M.V. and M.R.) according to the predefined eligibility criteria. To measure inter-rater reliability, Cohen’s kappa was calculated at the end of each selection step, and the calculated values were considered between 0.41 and 0.60 as moderate, 0.61 and 0.80 as substantial, and 0.81 and 1 as an almost perfect agreement [35]. In the case of a discrepancy, conflicts were resolved by a third review author (K.O.). Reference lists of eligible studies to the qualitative synthesis were also assessed manually to identify any additional records.

2.6. Data Collection Process

The following data were collected by M.V. and T.L. independently into standardised electronic spreadsheets in Microsoft Excel 2019\(^\circledR\) (Microsoft, Redmond, WA, USA), including characteristics of studies (year of publication, number of centres and country), demographic data of patients (i.e., age, Physical Status Classification System of the American Society of Anesthesiology), type and duration of surgery, characteristics of the induction and the maintenance of anaesthesia, aspects of perioperative treatment including protocol of goal-directed fluid regimen and the applied haemodynamic devices in the intervention group, protocol of fluid administration in the control group, protocol of pre- and postoperative fluid therapy, postoperative overall complications with predefined criteria of the studies, length of hospital stay, quantity and type of fluids administered intraoperatively, intraoperative urinary output, lactate levels at the end of the operation, and time to first flatus and stool in the postoperative period.

2.7. Synthesis of Results and Effect Measures

Forest plots were used to display the results of the meta-analysis. Pooled risk ratios (RRs) with 95% confidence intervals (CI) were calculated for dichotomous outcomes and weighted mean difference (WMD) with 95% CI for continuous outcomes. In the case of urinary output, standardised mean difference (SMD) was calculated for the average operation length. Data were converted from median and first and third quartile to mean and standard deviation, if data were reported in the former, according to the method of Wan (2014) [36]. Sensitivity analyses were also carried out, omitting one study and calculating the summary of RR, WMD, or SMD with 95% CI to investigate the influence of a single study on the final estimation.

A random-effect model was applied in all analyses with the estimation of DerSimonian and Laird [37]. Statistical heterogeneity was analysed using the I\(^2\) and \(\chi^2\) tests to gain probability values; \(p < 0.10\) was defined to indicate significant heterogeneity. The I\(^2\) test represents the percentage of total variation across studies because of heterogeneity. I\(^2\) values of 25–50%, 50–75%, and 75–100% corresponded to low, moderate, and high heterogeneity, respectively, on the basis of the Cochrane’s handbook [38]. All data management and statistical analyses were performed with Stata 16 SE (Stata Corp, College Station, TX, USA).
2.8. Study Risk of Bias Assessment and Reporting Bias Assessment

To identify the risk of bias of the included studies, two review authors (M.V. and M.R.) used RoB 2, a revised Cochrane Collaboration’s risk of bias tool for randomised trials [39]. The included studies were evaluated according to all five domains for each outcome (randomisation process, deviations from intended interventions, missing outcome data, measurement of the outcome, selections of the reported result) and finally, the overall risk of bias was classified as low, some concerns, or high. Discrepancies were resolved by a third review author (K.O.). The presence of publication bias was assessed by visual inspection of Funnel plots for lack of asymmetry [40]. The Egger’s test was not performed due to the low number of studies.

2.9. Certainty Assessment

Quality of evidence (QoE) was evaluated by M.V. and supervised by Z.M. with the help of the GRADE profiler (GRADEpro) according to the GRADE approach recommended by the Cochrane Collaboration [41–43]. The following domains were appraised: risk of bias; indirectness of evidence; serious inconsistency; imprecision of effect estimates; and other considerations such as publication bias, large effect, and plausible confounding.

3. Results

3.1. Study Selection

The selection process is detailed in Figure 1. Our search resulted in 5485 records from five databases (PUBMED®, Embase®, CENTRAL, Web of Science, and SCOPUS®). Finally, 15 RCTs were included in the qualitative synthesis [44–58], and in one RCT (Cho and colleagues), two types of GDFT protocols were implemented [46]. According to our selection criteria, it was not possible to decide which group should be included in the quantitative synthesis, and therefore we decided to include this study only in the qualitative synthesis. Eleven studies were included in the quantitative synthesis [47–54,56–58].

3.2. Study Characteristics

Baseline characteristics and demographic data for the included studies are presented in Table 1 and Table S3. A total of 835 patients from 11 studies were included in the quantitative synthesis. During the intraoperative period, 419 patients received GDFT, and 416 received N-GDFT. Nine out of eleven studies reported data on age; the mean age was 55.6 years in the GDFT group and 54.8 years in the N-GDFT group. The rest of the patients’ baseline characteristics and length of operation are detailed in Table S3 and Figure S1.
Figure 1. PRISMA flowchart of selection.
Table 1. Characteristics of included studies.

| Author (Year)          | Type of Surgery                                   | Preoperative Fluid Protocol | Haemodynamic Technology  | Primary Goal           | Intraoperative Fluid Protocol | Basis                        | Type of Fluid Protocol | Type of Fluid                  | Postoperative Fluid Protocol | Primary Outcome                                                                 |
|------------------------|---------------------------------------------------|-----------------------------|--------------------------|------------------------|-------------------------------|------------------------------|----------------------------|-------------------------------|-------------------------------|---------------------------------------------------------------------------------|
| Brandstrup (2012) [44] | Elective laparoscopic colorectal resection        | 0.9% saline UD *            | Oesophageal Doppler      | SV < 10%               | 200 mL VOLUVEN®              | Replacement of lost blood     | VOLUVEN® daily 2000 mL        | Overall postoperative complications                                               |
|                        |                                                   | N-GDFT                      |                          |                        | 200 mL VOLUVEN®              | Replacement of lost blood     |                             |                                |                                |
| Calvo-Vecino (2018) [45]| Laparoscopic gastrointestinal, urological, gynaecological | N/A                         | Oesophageal Doppler      | SV < 10%               | 250 mL VOLUVEN®, Lactated Ringer | 0 mL kg⁻¹ bw⁻¹                | None                        | Lactated Ringer                | N/A                           | Moderate or severe postoperative complications                                   |
|                        |                                                   | N-GDFT                      |                          |                        | 3-5 mL kg⁻¹ bw⁻¹              | Lactated Ringer               |                             |                                |                                |
| Cho (2021) [46]        | Laparoscopic sleeve gastrectomy                   | 4/2/1                       | Arterial waveform-derived | SVV < 10%             | 100 mL 6% hydroxyethyl starch 130/0.4 | 4 mL kg⁻¹ bw⁻¹                | Lactated Ringer or Saline 0.9% | N/A                           | Postoperative nausea and vomiting                                               |
|                        |                                                   | N-GDFT                      | Arterial waveform-derived | SVV < 10%             | 100 mL Lactated Ringer       | 4 mL kg⁻¹ bw⁻¹                | Lactated Ringer or Saline 0.9% |                                |                                |
|                        |                                                   |                             |                          |                        |                               | 4 mL kg⁻¹ bw⁻¹                | Lactated Ringer or Saline 0.9% |                                |                                |
| Demirel (2017) [47]    | Laparoscopic RYGB surgery                         | N/A                         | Pulse oximetry           | PVI < 14%              | 250 mL Gelofusine®            | 2 mL kg⁻¹ bw⁻¹                | 0.9% NaCl or Lactated Ringer 0.9% | N/A                           | Perioperative lactate, creatinine levels, hemodynamic variables                  |
|                        |                                                   | N-GDFT                      |                          |                        | 4-8 mL kg⁻¹ bw⁻¹              | Lactated Ringer              |                             |                                |                                |
| Gomez-Izquierdo (2017) [48]| Laparoscopic colorectal                           | 4/2/1                       | Oesophageal Doppler      | SV < 10%               | 200 mL VOLUVEN®              | 1.5 mL kg⁻¹ bw⁻¹              | Lactated Ringer              | 1.5 mL kg⁻¹/bw⁻¹/h⁻¹ in Surgical Department                                | Primary postoperative ileus                                                                 |
|                        |                                                   | N-GDFT                      |                          |                        | 5 mL kg⁻³ bw⁻¹                | VOLUVEN®                      |                             |                                |                                |
| Joosten (2018) [49]    | Laparoscopic colorectal, gynaecological, urological | N/A                         | Arterial waveform-derived | SVV < 13%             | 100 mL PlasmaLyte®           | 0 mL kg⁻¹ bw⁻¹                | None                        | N/A                           | Percentage of intraoperative time spent within defined haemodynamic targets (CI > 2.5 L/min/m² and/or an SVV < 13%) |
|                        |                                                   | N-GDFT                      |                          |                        | 6% hydroxyethyl starch 130/0.4 | 4 mL kg⁻¹ bw⁻¹                | PlasmaLyte®                  |                                |                                |
| Li (2021) [50]         | Laparoscopic radical resection of lower cervical cancer | N/A                         | Arterial waveform-derived | SVV < 13%             | 250 mL 6% hydroxyethyl starch 130/0.4 | 500 mL                      | Lactated Ringer              | N/A                           | Appearance of first bowel sounds, time to first flatus, lengths of hospital stay, incidence of postoperative nausea and vomiting |
|                        |                                                   | N-GDFT                      |                          |                        | 6% hydroxyethyl starch 130/0.4 | N/A                         | Lactated Ringer              |                                |                                |
| Liu (2019) [51]        | Laparoscopic colorectal                           | 5 mL kg⁻¹ bw⁻¹ before anaesthesia | Arterial waveform-derived | SVV < 13%             | 200 mL Colloid solution UD   | 2 mL kg⁻¹ bw⁻¹                | Lactated Ringer              | N/A                           | Haemodynamic variables and tissue oxygen saturations intraoperatively and at the end of operation |
|                        |                                                   | N-GDFT                      |                          |                        | Colloid solution UD           | 5 mL kg⁻¹ bw⁻¹                | Lactated Ringer              |                                |                                |
Table 1. Cont.

| Author (Year)          | Type of Surgery                  | Preoperative Fluid Protocol | Haemodynamic Technology | Primary Goal | Bolus               | Type of Fluid   | Basis         | Type of Fluid | Postoperative Fluid Protocol | Primary Outcome                                                                 |
|------------------------|----------------------------------|----------------------------|-------------------------|--------------|---------------------|----------------|---------------|---------------|-------------------------------|---------------------------------------------------------------------------------|
| Mei (2018) [52]        | Laparoscopic precision hepatectomy | N/A                        | Arterial waveform-derived | SVV < 13%    | 3 mL kg⁻¹ bw⁻¹ 10 mL kg⁻¹ bw⁻¹ | Colloid solution UD  | Crystalloid UD | Crystalloid UD | N/A                          | MAP, SVV, CVP, and lactate levels through the intraoperative period and at the end of surgery |
| Muhlbacher (2021) [53] | Laparoscopic gastric bypass       | 500 mL Lactated-Ringer     | Oesophageal Doppler     | SV < 10%     | 250 mL AAE         | Lactated Ringer | Lactated Ringer | Lactated Ringer | AAE in PACU                    | Perioperative subcutaneous tissue oxygen tension (upper arm)                     |
| Ratti (2016) [54]      | Laparoscopic liver resection      | ERAS **                    | Arterial waveform-derived | SVV < 12%    | N/A                 | Crystalloid UD | N/A           | Crystalloid UD | ERAS **                      | Rate and reasons of conversion                                                   |
| Senagore (2009) [55]   | Laparoscopic colorectal           | N/A                        | Oesophageal Doppler     | SV < 10%     | 300 mL AAE         | Lactated Ringer | 5 mL kg⁻¹ bw⁻¹ | Lactated Ringer | N/A                          | Length of hospital stay                                                          |
| Tang (2021) [56]       | Laparoscopic radical gastrectomy | 250 mL warm sugar water per os | Arterial waveform-derived | SVV < 13%    | 250 mL AAE         | 6% hydroxyethyl starch 130/0.4 | N/A           | Crystalloid UD | N/A                          | Incidence of postoperative complications                                         |
| Wen (2016) [57]        | Laparoscopic gastrectomy          | N/A                        | Arterial waveform-derived | SVV < 13%    | 3 mL kg⁻¹ bw⁻¹ 5 mL kg⁻¹ bw⁻¹ | 6% hydroxyethyl starch 130/0.4 | Lactated Ringer | Lactated Ringer | N/A                          | Changes of haemodynamic variables and application of vasoactive drugs            |
| Yin (2018) [58]        | Laparoscopic colorectal           | N/A                        | Bioreactance            | SVV < 13%    | 250 mL AAE         | 6% hydroxyethyl starch 130/0.4 | 8 mL kg⁻¹ bw⁻¹ | Saline UD      | N/A                          | Moderate or severe postoperative complications within 30 days                    |

Included in systematic review only. Included both in the quantitative and qualitative synthesis. *: if fluid intake was under 500 mL; **: according to ERAS protocol for liver surgery; 4/2/1: 4 mL per kilograms of bodyweight for the first 10 kg, 2 mL kg⁻¹ bw⁻¹ to the second 10 kg, 1 mL kg⁻¹ bw⁻¹ to the other kg bw⁻¹. Abbreviations: N-GDFT: non-goal-directed fluid therapy, SV: stroke volume, SVV: stroke volume variation, PVI: Pleth Variability Index, UD: undetermined, AAE: according to the anaesthetist evaluation, N/A: data not available, PACU: post-anaesthesia care unit, CI: Cardiac Index, CVP: central venous pressure, NaCl: natrium chloride, RYBG: Roux-en-Y gastric bypass surgery, MAP: mean arterial pressure, ERAS: enhanced recovery after surgery, bw: bodyweight.
3.3. Results of Syntheses and Individual Studies

3.3.1. Length of Hospital Stay

Length of hospital stay was significantly shorter in the GDFT group (WMD: −1.18 days, 95% CI: −1.84 to −0.53) according to data from eight RCTs [48–52,54,56,58], but data were considered highly heterogeneous (I² = 80.1%, p < 0.01) (Figure 2). As an implementation of the ERAS protocol could have a substantial effect on hospital stay, we performed subgroup analysis on studies that used ERAS protocols and those that did not. Only three studies implemented ERAS and N-GDFT (WMD: −1.18 days, 95% CI: −2.79 to 0.43), and no significant difference was found between the two groups (WMD: −1.28 days, 95% CI: −2.12 to −0.44); however, high heterogeneity was detected (I² = 85.5%, p < 0.01). No influential study was identified by the leave-one-out sensitivity analysis (Figure S17). Data for length of hospital stay were presented in one further study (Cho and colleges) that was not included in our meta-analysis [46], for reasons detailed previously. Nevertheless, no significant differences were observed between the two goal-directed groups and the controls (4.40 and 4.40 days in the two GDFT groups versus 4.52 days in the non-goal-directed group, p = 0.78).

| Studies                  | WMD (95% CI)       | GDT N, Mean (SD) | N-GDT N, Mean (SD) | Weight % |
|--------------------------|--------------------|------------------|--------------------|-----------|
| **ERAS**                 |                    |                  |                    |           |
| Tang 2021                | -2.40 (-4.25, -0.55) | 37.89 (3.7)      | 37.13 (4.4)        | 7.79      |
| Rani 2016               | -1.30 (-4.57, 1.17)  | 45.53 (6.1)      | 45.77 (7.7)        | 4.15      |
| Gomez-Izquierdo 2017     | -0.20 (-0.81, 0.41)  | 64.41 (1.5)      | 64.42 (2.1)        | 17.63     |
| **Subtotal (I-squared = 64.4%, p = 0.000)** | **-1.18 (-2.70, 0.43)** | **146**          | **146**            | **29.57** |
| **Non-ERAS**             |                    |                  |                    |           |
| Vu et al. 2018          | -1.66 (-3.06, -0.24) | 73.17 (7.4)      | 73.17 (7.6)        | 18.21     |
| Mei 2018                | -1.00 (-1.47, -0.53) | 58.59 (1.3)      | 58.79 (1.3)        | 18.81     |
| Li 2021                 | -0.10 (-0.55, 0.35)  | 30.46 (6.3)      | 30.54 (5.4)        | 20.23     |
| Liu 2016                | -0.00 (-0.92, 0.32)  | 37.10 (2.3)      | 37.11 (2.6)        | 12.94     |
| Joosten 2018            | 0.40 (-3.17, 3.97)   | 19.33 (2.4)      | 19.33 (2.4)        | 8.24      |
| **Subtotal (I-squared = 85.5%, p = 0.000)** | **-1.28 (-2.12, -0.44)** | **167**          | **167**            | **70.45** |
| **Overall (I-squared = 80.1%, p = 0.000)** | **-1.18 (-1.84, -0.53)** | **313**          | **313**            | **100.00** |

**NOTE:** Weights are from random-effects analysis

Figure 2. Length of hospital stay (days). Length of hospital stay was significantly shorter in patients who received GDFT (WMD = −1.18 days; 95% CI = −1.84 days to −0.53 days) and also in the non-ERAS subgroup (WMD = −1.28 days; 95% CI = −2.12 days to −0.44 days). However, in the ERAS subgroup, our result was not significant (WMD = −1.18 days; 95% CI = −2.79 days to 0.43 days). Heterogeneity was high both in overall and in the non-ERAS group (I-squared = 80.1%; p < 0.01 and I-squared = 85.5%; p < 0.01), and moderate in the ERAS subgroup (I-squared = 64.4%; p = 0.06).

3.3.2. Readmission and Reoperation Rate

A 30-day readmission to the surgical ward and the emergency department were detailed only by Gomez-Izquierdo et al. [48]. No significant differences were found (8 out of 64, 12.0% versus 6 out of 64, 9.4%, p = 0.35; 3 out of 64, 20.0% versus 9 out of 64, 14.0%, p = 0.58, respectively). The reoperation rate was reported by both Gomez-Izquierdo et al. and Joosten et al. [48,49]. No significant differences were found between the GDFT and N-GDFT groups (1 out of 19, 5.0% versus 2 out of 20, 10.0%, p = 0.58; 1 out of 64, 3.1% and 3 out of 64, 4.7%, p = 0.62, respectively).
3.3.3. Overall Complications within 30 Days

Nine studies reported data for overall complications [44,45,48,49,51,54,56–58]; however only two fulfilled our criteria [44,48], and hence we were unable to perform a quantitative synthesis. In these two studies, there were no significant differences regarding this outcome (43.8% versus 39.1%, \( p = 0.59 \); 28.1% versus 26.3%, \( p = 0.86 \), respectively).

3.3.4. Recovery of Gastrointestinal Function as Indicated by Time to First Flatus and Time to First Stool

Five trials evaluated time to first stool [49,51,52,57,58], which was significantly reduced in patients receiving GDFT (WMD: \(-9.8\) h, 95% CI: \(-12.7\) to \(-7.0\); Figure 3A). The leave-one-out sensitivity analysis did not identify any influential study (Figure S18). Five further studies reported time to first flatus with significant difference between the two groups (WMD: \(-5.63\) h, 95% CI: \(-10.9\) to \(-0.4\) h) [48–50,56,57], but heterogeneity was high (I\(^2\) = 92.0%, \( p < 0.01 \); Figure 3B). According to the leave-one-out sensitivity analysis, omission of studies published by Tang, Wen, and Li would change the statistical significance (Figure S19).

### Table 3.1

| Studies               | WMD (95% CI)     | SD: standard deviation, GDFT N, Mean (SD) | N-GDFT N, Mean (SD) | Weight % |
|-----------------------|------------------|------------------------------------------|---------------------|----------|
| Joosten 2018          | -24.70 (-59.50, 10.10) | 20, 56.3 (21.5) | 19, 81 (74.5) | 0.67     |
| Yin 2018              | -14.60 (-27.75, -0.25) | 22, 72 (24) | 23, 86 (23) | 4.29     |
| Wen 2016              | -0.10 (-16.50, -3.90) | 40, 88.5 (10.2) | 40, 98.7 (17.6) | 20.37    |
| Mei 2018              | -9.60 (-13.09, -6.11) | 58, 38.4 (9.6) | 58, 48 (9.6) | 66.32    |
| Liu 2019              | -7.20 (-17.04, 2.64) | 37, 52.8 (21.6) | 37, 60 (21.6) | 8.36     |
| Overall               | -9.81 (-12.66, -6.97) | 177 | 177 | 100.00   |

NOTE: Weights are from random effects analysis. Favour GDFT | Favour N-GDFT

| Studies               | WMD (95% CI)     | SD: standard deviation, GDFT N, Mean (SD) | N-GDFT N, Mean (SD) | Weight % |
|-----------------------|------------------|------------------------------------------|---------------------|----------|
| Tang 2021             | -13.70 (-22.18, -5.22) | 37, 84.5 (19) | 37, 90.2 (18.2) | 14.51    |
| Wen 2016              | -9.50 (-14.33, -4.67) | 40, 76.1 (9.3) | 40, 85.6 (12.5) | 19.51    |
| Li 2021               | -8.70 (-10.14, -7.26) | 30, 43.7 (2.9) | 30, 52.4 (2.8) | 22.97    |
| Joosten 2019          | 0.00 (-3.01, 3.01) | 20, 23.3 (4.8) | 19, 23.3 (4.8) | 21.70    |
| Gomez-Izquierdo 2017  | 1.00 (-2.36, 4.36) | 56, 19.7 (9.9) | 59, 18.7 (8.4) | 21.32    |
| Overall               | -5.63 (-10.87, -0.38) | 183 | 185 | 100.00   |

NOTE: Weights are from random effects analysis. Favour GDFT | Favour N-GDFT

**Figure 3.** Time to first stool and time to first flatus. Time to first stool (A) was significantly reduced in patients receiving GDFT compared to the controls (WMD = \(-9.81\) h; 95% CI = \(-12.66\) h to \(-6.97\) h). No evidence was found for heterogeneity (I\(^2\) = 0.0%; \( p = 0.85 \)). Time to first flatus (B) was significantly reduced in the GDFT group compared to the controls (WMD = \(-5.63\) h; 95% CI = \(-10.87\) h to -0.38 h).
shortened in the GDFT group compared to the controls (WMD = −5.63 h; 95% CI = −10.87 h to 0.38 h). High heterogeneity was detected (I-squared = 92.0%; p < 0.01). WMD: weighted mean difference, SD: standard deviation, GDFT: goal-directed fluid therapy, N-GDFT: non-goal-directed fluid therapy, CI: confidence interval. p < 0.1 was considered significant.

3.3.5. Intraoperative Clinical Outcomes: Intraoperative Fluid and Vasopressor Requirement, Standardised Intraoperative Urinary Output and Lactate Levels at the End of the Operation

Data for clinical outcomes are shown in Figure 4. According to seven studies reporting data for intraoperative fluid requirement [48,49,51,53,56–58], patients undergoing GDFT received significantly less fluid than controls (WMD: −441 mL, 95% CI: −790 to −92 mL), with high heterogeneity (I² = 96.9%, p < 0.01). Leave-one-out sensitivity analysis did not report any influential study (Figure S20). Cho and colleagues reported similar data indicating that significantly less fluid (colloid) boluses were administered in the GDFT group versus controls (858 mL versus 1639 mL; p < 0.01) [46]. On the basis of the results of eight studies, fewer patients required vasopressors in the GDFT group [47–49,52,53,56,58], but statistical significance was not reached (RR: 0.90, 95% CI: 0.71 to 1.14). No influential study was detected by the leave-one-out sensitivity analysis (Figure S21). Cho et al. also provided data on intraoperative vasopressor requirement with no significant difference between the two GDFT groups as compared to the controls (44% and 24% versus 28%; p = 0.38) [46]. No significant difference was found in the intraoperative urinary output standardised for length of surgery (SMD: 5.69 mL h⁻¹, 95% CI: −2.16 to 13.54 mL h⁻¹). The leave-one-out sensitivity analysis did not identify any influential study (Figure S22). Serum lactate levels at the end of operation in the GDFT group were significantly lower compared to the N-GDFT group (WMD: −0.25 mmol L⁻¹, 95% CI: −0.36 to −0.14). There was no evidence of heterogeneity (I² = 42.7%, p = 0.175). Leave-one-out sensitivity analysis could not be performed due to the low number of studies.

Figure 4. Clinical outcomes at the end of operation. Intraoperative fluid requirement (A) was significantly lower (WMD = −440.84 mL; 95% CI −789.73 mL to −91.96 mL) in the GDFT group. High heterogeneity was detected (I-squared = 96.9%, p < 0.005). There was no significant difference in the number of patients requiring vasopressors intraoperatively (B) between the goal- and the non-goal-directed groups. (RR = 0.90; 95% CI = 0.71 to 1.14). Low heterogeneity was found (I-squared = 44.0%; p < 0.01). There was no significant difference in intraoperative urinary output standardised for length of surgery (SMD = 5.69 mL h⁻¹; 95% CI = −2.16 to 13.54 mL h⁻¹). Data were not considered heterogeneous (I-squared = 0.0%; p = 0.96). Serum lactate levels (D) were significantly lower in the GDFT group compared to N-GDFT (WMD = −0.25 mmol L⁻¹; 95% CI −0.36 mmol/L to −0.14 mmol L⁻¹). There is no evidence for heterogeneity (I-squared = 42.7%; p = 0.18). WMD: weighted mean difference.
Clinical outcomes at the end of operation. Intraoperative fluid requirement (A) was significantly lower (WMD = −440.84 mL; 95% CI: −789.73 mL to −91.96 mL) in the GDFT group. High heterogeneity was detected (I-squared = 96.9%, p < 0.01). There was no significant difference in the number of patients requiring vasopressors intraoperatively (B) between the goal- and the non-goal-directed groups. (RR = 0.90; 95% CI = 0.71 to 1.14). Low heterogeneity was found (I-squared = 44.0%; p < 0.01). There was no significant difference in intraoperative urinary output standardised for length of surgery (C) between the two groups (SMD = 5.69 mL h\(^{-1}\); 95% CI = −2.16 mL h\(^{-1}\) to 13.54 mL h\(^{-1}\)). Data were not considered heterogeneous (I-squared = 0.0%; p = 0.96). Serum lactate levels (D) were significantly lower in the GDFT group compared to N-GDFT (WMD = −0.25 mmol L\(^{-1}\); 95% CI = −0.36 mmol/ L to −0.14 mmol L\(^{-1}\)). There is no evidence for heterogeneity (I-squared = 42.7%; p = 0.18). WMD: weighted mean difference, SMD: standardised mean difference, RR: risk ratio, SD: standard deviation. GDFT: goal-directed fluid therapy, N-GDFT: non-goal-directed fluid therapy, CI: confidence interval.

3.4. Risk of Bias in Studies and Certainty of Evidence

Figures S8–S16 summarise the risk of bias assessment for all outcomes. All studies were judged as low risk or with some concerns.

A certainty of evidence table, including reasons for downgrading of the evidence level, is detailed in Table S4 and Figures S2–S7. Certainty of evidence was considered very low for intraoperative fluid requirement, intraoperative vasopressor requirement, urinary output, time to first flatus, and length of hospital stay, whereas it was low for serum lactate levels at the end of the operation and time to first stool after the operation (Table S4).

4. Discussion

The main findings of our meta-analysis are that patients treated with GDFT received less fluid during surgery, had lower serum lactate levels, both the first flatus and stool appeared earlier, and their hospital stay was also reduced compared to the N-GDFT-treated patients.

4.1. Summary of Evidence

Laparoscopic surgery may inflict profound effects on macro haemodynamic variables, resulting in elevated central venous and right atrial pressure, decreased cardiac output.
and stroke volume, and higher mean arterial pressure and systemic vascular resistance, due to elevated intraabdominal pressure and hypercarbia [4,5,59]. These can lead to decreased renal and splanchnic circulation, which are often responsible for unfavourable postoperative outcomes [5,60].

Adequate fluid management during surgery is of utmost importance to maintain adequate perfusion and oxygen delivery to the tissues. As both hypo- and hypervolaemia can be harmful, targeting fluid therapy to the patients’ individual needs is mandatory [61,62]. Fluid restriction per se, recommended in several guidelines as superior to liberal strategy [29,30], may reduce blood flow to the gastrointestinal tract, which may prolong the gastrointestinal recovery [5,63–65], impairing renal perfusion and leading to higher incidence of acute kidney injury after surgery [66]. Both effects can be precipitated during the pneumoperitoneum. Hypervolaemia and excessive fluid administration can also be harmful by causing interstitial oedema, which also impairs perfusion and oxygen uptake [67], which may lead to higher chance to surgical postoperative morbidity [68].

Conventional variables, such as heart rate and blood pressure, cannot predict fluid responsiveness and tell us little about tissue perfusion. Advanced haemodynamic monitoring (invasive, less invasive, non-invasive) has been tried and tested intensively for decades [69], but discussing these are beyond the scope of the current article. One advantage of using haemodynamic monitoring is being able to implement GDFT [62,70]. In the current meta-analysis, we included studies that compared GDFT to N-GDFT in patients undergoing laparoscopic surgery.

Our results suggest that GDFT may lead to a shorter length of hospital stay. This finding was significant and can also be considered compelling in the clinical practice. This observation is in accordance with previously reported results [71–73]. However, no significant difference was detected in those studies that implemented the ERAS. Further investigations are necessary whether GDFT combined with ERAS or other fast-track surgery protocols provides additional benefit of shorter hospitalisation or not.

One of the most important results of the current meta-analysis is that GDFT was associated with faster gastrointestinal recovery as indicated by shorter time to first stool. Although this outcome may be seen as of particular importance only after bowel surgery, there is substantial evidence to support that any abdominal surgery that applies pneumoperitoneum can lead to impaired bowel function [5,74]. Former studies suggested that the best way to evaluate the functional recovery of the gastrointestinal tract after surgery is the time to tolerate solid food and to pass the first stool. This is in alignment with our findings. These findings suggest that using GDFT may help to individualise fluid management and had not been shown in the two previous meta-analyses [23,24].

Conventional monitoring of heart rate and blood pressure have been shown to be inadequate measures of perfusion in general, and hence normal values do not exclude splanchnic hypoperfusion causing decreased oxygen delivery, resulting in anaerobic glycolysis and accumulation of lactate. The latter is an important marker to detect insufficient oxygen supplementation [75]. Although the lactate levels at the end of the operation were in the acceptable therapeutic range in both groups, levels were lower in the GDFT patients as compared to the N-GDFT group, indicating that the lesser amount of intraoperative fluid administration did not cause underfilling and/or consequential hypoperfusion. Unfortunately, previous meta-analyses did not report on serum lactate levels directly following the operation. However, our findings are in accordance with that of Forget et al. [76]. In their study, significantly lower lactate levels were reported in the GDFT group (GDFT: 1.2 mmol L⁻¹; CI: 1–1.4 CI versus N-GDFT 1.6 mmol L⁻¹; CI: 1.2–2.0). It is important to note that they confined their investigation to the intraoperative period.

4.2. Strengths and Limitations

This is the first meta-analysis that has investigated the effects of GDFT versus N-GDFT specifically in laparoscopic abdominal surgery. Our study reflects on both physiological issues at the end of the operation and measures of gastrointestinal recovery, length of
hospital stay, and overall complications and readmission rate. Furthermore, the trials originate from several countries and continents, which increases the representative value of the results. Finally, the studies included in our analysis were published mainly in the last five years, and hence our results provide data that have not been considered yet in recent guidelines.

Our meta-analysis also has some limitations. First, most of the trials were single-centre RCTs with a low number of patients, which probably decreases the external validity of the studies. This may explain the high heterogeneity of several analyses. Second, the applied haemodynamic monitoring technologies in the GDFT group and the fluid administration regimens in the controls showed great variability, which may also point out the high heterogeneity for length of hospital stay, time to first flatus, and intraoperative fluid requirement. Third, we were unable to perform subgroup analysis on the type fluids used (i.e., crystalloids vs. colloids) due to the quality and quantity of the data reported on the outcomes we investigated. Furthermore, we were unable to perform a quantitative analysis for the overall complication rates due heterogeneous reporting on complications.

5. Conclusions

To our knowledge, this is the first and most comprehensive meta-analysis to date that reports on the effects of intraoperative GDFT resulting in less intravenous fluid administration, lower postoperative lactate levels, and enhanced recovery of the gastrointestinal function, which may lead to reduced hospital stay in patients undergoing elective abdominal laparoscopic surgery. Whether GDFT would result in overall advantageous outcomes including healthcare costs as compared to the generalised “fluid restriction” strategy recommended by the ERAS protocols in laparoscopic surgery has to be determined by further research.

Supplementary Materials: The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/jpm12050734/s1, Figure S1: Operation time; Figure S2: Funnel plot—Length of hospital stay; Figure S3 Funnel plot—Time to first stool; Figure S4: Funnel plot—Time to first flatus; Figure S5: Funnel plot—Intraoperative fluid requirement; Figure S6: Funnel plot—Intraoperative vasopressor requirement; Figure S7: Funnel plot—Intraoperative urinary output standardized for the length of the surgery; Figure S8: RoB—Length of hospital stay; Figure S9: RoB—Reoperation and readmission rate; Figure S10: RoB—Overall complication; Figure S11: RoB—Time to first flatus; Figure S12: RoB—Time to first stool; Figure S13: RoB—Intraoperative fluid requirement; Figure S14: RoB—Intraoperative vasopressor requirement; Figure S15: RoB—Intraoperative urinary output; Figure S16: RoB—Serum lactate levels at the end of the operation; Figure S17: Leave-one-out analysis—Length of hospital stay; Figure S18: Leave-one-out analysis—Time to first stool; Figure S19: Leave-one-out analysis—Time to first flatus; Figure S20: Leave-one-out analysis—Intraoperative fluid requirement; Figure S21: Leave-one-out analysis—Intraoperative vasopressor requirement; Figure S22: Leave-one-out analysis—Intraoperative urinary output; Table S1: List of accepted haemodynamic measurement as Goal-directed-fluid therapy; Table S2: Detailed search; Table S3: Baseline characteristics of the patients and length of operation of the included studies; Table S4: Certainty assessment.

Author Contributions: Conceptualisation, M.V. and Z.M.; methodology, K.O.; software, N.G.; validation, K.O. and M.R.; formal analysis, N.G. and N.F.; resources, P.H.; data curation, M.R. and T.L.; writing—original draft preparation, M.V.; writing—review and editing, Z.M.; visualisation, M.T.; supervision, P.H. and S.A.; project administration, P.H.; funding acquisition, P.H. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the Economic Development and Innovation Operational Programme Grant (GINOP-2.3.2-15-2016-00048—STAY ALIVE), Competence Centre for Health Data Analysis, Data Utilisation and Smart Device and Technology Development at the University of Pécs (GINOP-2.3.4-15-2020-00010) and the Hungarian National Research, Development and Innovation Office (Grant No. K 138816).
**Institutional Review Board Statement:** The authors declare that the work described was carried out in accordance with the Declaration of Helsinki of the World Medical Association revised in 2013 for experiments involving humans, as well as in accordance with the EU Directive 2010/63/EU for animal experiments.

**Informed Consent Statement:** The authors declare that this report does not contain any personal information that could lead to the identification of the patient(s).

**Data Availability Statement:** The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

**Acknowledgments:** We would like to thank Szabolcs Kiss and Fanni Dembrovsky for the methodological workshops and advice.

**Conflicts of Interest:** Z.M. has regularly honoraria for lectures for PULSION Medical, Germany (member of the Getinge Group), and ThermoFisher Scientific, and he has been a senior medical director at CytoSorbents Europe, Berlin, Germany. The other authors declare no conflict of interest.

**References**

1. Buia, A.; Stockhausen, F.; Hanisch, E. Laparoscopic surgery: A qualified systematic review. *World J. Methodol.* 2015, 5, 238–254. [CrossRef] [PubMed]

2. Pascual, M.; Salvans, S.; Pera, M. Laparoscopic colorectal surgery: Current status and implementation of the latest technological innovations. *World J. Gastroenterol.* 2016, 22, 704–717. [CrossRef] [PubMed]

3. Concha, M.R.; Mertz, V.F.; Cortinez, L.I.; Gonzalez, K.A.; Butte, J.M.; Lopez, F.; Pinedo, G.; Zuniga, A. The Volume of Lactated Ringer’s Solution Required to Maintain Preload and Cardiac Index during Open and Laparoscopic Surgery. *Anesth. Analg.* 2009, 108, 616–621. [CrossRef] [PubMed]

4. Safran, D.B.; Orlando, R., III. Physiologic effects of pneumoperitoneum. *Am. J. Surg.* 1994, 167, 281–286. [CrossRef]

5. Atkinson, T.M.; Giraud, G.D.; Togioka, B.M.; Jones, D.B.; Cigarroa, J.E. Cardiovascular and Ventilatory Consequences of Laparoscopic Surgery. *Circulation* 2017, 135, 700–710. [CrossRef]

6. Oti, C.; Mahendran, M; Sabir, N. Anaesthesia for laparoscopic surgery. *Br. J. Hosp. Med.* 2016, 77, 24–28. [CrossRef]

7. Cecconi, M.; Corredor, C.; Arulkumaran, N.; Abuella, G.; Ball, J.; Grounds, R.M.; Hamilton, M.; Rhodes, A. Clinical review: Goal-directed therapy-what is the evidence in surgical patients? *Crit. Care* 2013, 17, 209. [CrossRef]

8. Gustafsson, U.O.; Scott, M.J.; Hubner, M.; Nygren, J.; Demartines, N.; Francis, N.; Rockall, T.A.; Young-Fadok, T.M.; Hill, A.G.; Soop, M.; et al. Guidelines for Perioperative Care in Elective Colorectal Surgery: Enhanced Recovery After Surgery (ERAS®) Society Recommendations: 2018. *World J. Surg.* 2018, 43, 659–695. [CrossRef]

9. Melloul, E.; Hübner, M.; Scott, M.; Snowden, C.; Prentis, J.; Dejong, C.H.; Garden, O.J.; Farges, O.; Kokudo, N.; Vauthey, J.N.; et al. Guidelines for Perioperative Care for Liver Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations. *World J. Surg.* 2016, 40, 2425–2440. [CrossRef]

10. Nygren, J.; Thacker, J.; Carli, F.; Fearon, K.C.H.; Norderval, S.; Ljungqvist, O.; Sjöqvist, F.; Soop, M.; Ramirez, J. Enhanced Recovery After Surgery Society. Guidelines for perioperative care in elective rectal/pelvic surgery: Enhanced Recovery after Surgery (ERAS®) Society recommendations. *Clin. Nutr.* 2012, 31, 801–816. [CrossRef]

11. Larsson, J.F.; Svendsen, F.M.; Pedersen, V. Randomized clinical trial of the effect of pneumoperitoneum on cardiac function and haemodynamics during laparoscopic cholecystectomy. *Br. J. Surg.* 2004, 91, 848–854. [CrossRef] [PubMed]

12. Odeberg, S.; Ljungqvist, O.; Svenberg, T.; Gennedahl, P.; Bäckdahl, M.; von Rosen, A.; Sollevi, A. Haemodynamic effects of pneumoperitoneum and the influence of posture during anaesthesia for laparoscopic surgery. *Acta Anaesthesiol. Scand.* 1994, 38, 276–283. [CrossRef] [PubMed]

13. Porter, C.A.; Compton Rp Fauf-Walters, D.N.; Walters Dn Fauf-Browder, I.W.; Browder, I.W. Benefits of pulmonary artery catheter and transesophageal echocardiographic monitoring in laparoscopic cholecystectomy patients with cardiac disease. *Am. J. Surg.* 1995, 169, 202–206. [CrossRef]

14. Hein, H.A.T.; Joshi, G.P.; Ramsay, M.A.E.; Fox, L.G.; Gawey, B.J.; Hellman, C.L.; Arnold, J.C. Hemodynamic changes during laparoscopic cholecystectomy in patients with severe cardiac disease. *J. Clin. Anesth.* 1997, 9, 261–265. [CrossRef]

15. Miller Te Fau-Roche, A.M.; Roche Am Fau-Walters, D.N.; Walters Dn Fau-Browder, I.W.; Browder, I.W. Benefits of pulmonary artery catheter and transesophageal echocardiographic monitoring in laparoscopic cholecystectomy patients with severe cardiac disease. *J. Clin. Anesth.* 1997, 9, 261–265. [CrossRef]

16. Gehrig, S.T.; do Nascimento, P. Maintaining Tissue Perfusion in High-Risk Surgical Patients: A Systematic Review of Randomized Clinical Trials. *Anesth. Analg.* 2011, 112, 1274–1276. [CrossRef]

17. Gurgel, S.T.; do Nascimento, P. Maintaining Tissue Perfusion in High-Risk Surgical Patients: A Systematic Review of Randomized Clinical Trials. *Anesth. Analg.* 2011, 112, 1384–1391. [CrossRef]

18. Hamilton, M.A.; Cecconi, M.; Rhodes, A. A systematic review and meta-analysis on the use of preemptive hemodynamic intervention to improve postoperative outcomes in moderate and high-risk surgical patients. *Anesth. Analg.* 2011, 112, 1392–1402. [CrossRef]

19. Srinivasa, S.; Taylor, M.H.; Singh, P.P.; Yu, T.C.; Soop, M.; Hill, A.G. Randomized clinical trial of goal-directed fluid therapy within an enhanced recovery protocol for elective colectomy. *Br. J. Surg.* 2013, 100, 66–74. [CrossRef]
19. Miller, T.E.; Roche, A.M.; Mythen, M. Fluid management and goal-directed therapy as an adjunct to Enhanced Recovery After Surgery (ERAS). *Can. J. Anesth.* 2015, 62, 158–168. [CrossRef]

20. Wrozek, A.; Jakowicka-Wordliczek, J.; Zajaczkowska, R.; Serednicki, W.T.; Jankowski, M.; Bala, M.M.; Swierz, M.J.; Polak, M.; Wordliczek, J. Perioperative restrictive versus goal-directed fluid therapy for adults undergoing major non-cardiac surgery. *Cochrane Database Syst. Rev.*, 2019, 12, Cd012767. [CrossRef]

21. Xu, C.; Peng, J.; Liu, S.; Huang, Y.; Guo, X.; Xiao, H.; Qi, D. Goal-directed fluid therapy versus conventional fluid therapy in colorectal surgery: A meta-analysis of randomized controlled trials. *Int. J. Surg.*, 2018, 56, 264–273. [CrossRef]

22. Chong, M.A.; Wang, Y.; Berbenetz, N.M.; McConachie, I. Does goal-directed haemodynamic and fluid therapy improve peri-operative outcomes? A systematic review and meta-analysis. *Eur. J. Anaesthesiol.*, 2018, 35, 469–483. [CrossRef] [PubMed]

23. Messina, A.A.-O.; Robba, C.; Calabrò, L.; Zambrilli, D.; Iannuzzi, F.; Molinari, E.; Scarano, S.; Battaglini, D.; Baggiani, M.; de Mattei, G.; et al. Association between perioperative fluid administration and postoperative outcomes: A 20-year systematic review and a meta-analysis of randomized goal-directed trials in major visceral/noncardiac surgery. *Crit. Care* 2021, 25, 43. [CrossRef] [PubMed]

24. Gómez-Izquierdo, J.C.; Feldman, L.S.; Carli, F.; Baldini, G. Meta-analysis of the effect of goal-directed therapy on bowel function after abdominal surgery. *Br. J. Surg.* 2015, 102, 577–589. [CrossRef] [PubMed]

25. Rollins, K.E.; Mathias, N.C.; Lobo, D.N. Meta-analysis of goal-directed fluid therapy using transoesophageal Doppler monitoring in patients undergoing elective colorectal surgery. *BJ Open* 2019, 3, 606–616. [CrossRef]

26. Arulkumaran, N.; Corredor, C.A.; Hamilton, M.A.; Ball, J.; Grounds, R.M.; Rhodes, A.; Cecconi, M. Cardiac complications associated with goal-directed therapy in high-risk surgical patients: A meta-analysis. *Br. J. Anaesth.* 2014, 112, 648–659. [CrossRef]

27. Kaufmann, T.A.-O.; Clement, R.P.; Scheeren, T.W.L.; Saugel, B.; Keus, F.; van der Horst, I.C.C. Perioperative goal-directed therapy: A systematic review without meta-analysis. *Anaesthesia* 2018, 62, 1340–1355. [CrossRef]

28. Zhao, X.; Tian, L.; Brackett, A.; Dai, F.; Xu, J.; Meng, L. Classification and differential effectiveness of goal-directed hemodynamic therapies in surgical patients: A network meta-analysis of randomized controlled trials. *J. Crit. Care* 2021, 61, 152–161. [CrossRef]

29. Feldheiser, A.; Aziz, O.; Baldini, G.; Cox, B.P.; Fearon, K.C.; Feldman, L.S.; Gan, T.J.; Kennedy, R.H.; Ljungqvist, O.; Lobo, D.N.; et al. Enhanced Recovery After Surgery for gastrointestinal surgery, part 2: Consensus statement for anaesthesia practice. *Acta Anaesthesiol. Scand.* 2016, 60, 289–334. [CrossRef]

30. McEvoy, M.D.; Scott, M.J.; Gordon, D.B.; Grant, S.A.; Thacker, J.K.M.; Wu, C.L.; Gan, T.J.; Mythen, M.G.; Shaw, A.D.; Miller, T.E. American Society for Enhanced Recovery (ASER) and Perioperative Quality Initiative (POQI) joint consensus statement on optimal analgesia within an enhanced recovery pathway for colorectal surgery: Part 1—from the preoperative period to PACU. *Perioper. Med.* 2017, 6, 8. [CrossRef]

31. Thiele, R.H.; Raghunathan, K.; Brudney, C.S.; Lobo, D.N.; Martin, D.; Senagore, A.; Cannesson, M.; Gan, T.J.; Mythen, M.M.; Shaw, A.D.; et al. American Society for Enhanced Recovery (ASER) and Perioperative Quality Initiative (POQI) joint consensus statement on perioperative fluid management within an enhanced recovery pathway for colorectal surgery. *Perioper. Med.* 2016, 17, 24. [CrossRef] [PubMed]

32. Page, M.J.-O.; Moher, D.; Bousuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews. *BMJ* 2021, 372, n160. [CrossRef] [PubMed]

33. Meng, L.; Heerdt, P.M. Perioperative goal-directed haemodynamic therapy based on flow parameters: A concept in evolution. *Br. J. Anaesth.* 2016, 117, iii3–iii17. [CrossRef] [PubMed]

34. Bundgaard-Nielsen, M.; Holte, K.; Secher, N.H.; Kehlet, H. Monitoring of peri-operative fluid administration by individualized goal-directed therapy. *Acta Anaesthesiol. Scand.* 2007, 51, 331–340. [CrossRef] [PubMed]

35. Landis, J.R.; Koch, G.G. The measurement of observer agreement for categorical data. *Biometrics* 1977, 33, 159–174. [CrossRef]

36. Wan, X.; Wang, W.; Liu, J.; Tong, T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med. Res. Methodol.* 2014, 14, 135. [CrossRef]

37. DerSimonian, R.; Fau-Laird, N.; Laird, N. Meta-analysis in clinical trials. *Control Clin. Trials.* 1986, 7, 177–188. [CrossRef]

38. Higgins, T.J.; Chandler, J.; Cumpston, M.; Li, T.; Page, M.J.; Welch, V.A. (Eds.) Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane. 2021. Available online: www.training.cochrane.org/handbook (accessed on 26 April 2022).

39. Sterne, J.A.-O.; Savović, J.; Page, M.J.; Elbers, R.G.; Blencowe, N.S.; Boutron, I.; Cates, C.J.; Cheng, H.Y.; Corbett, M.S.; Eldridge, S.M.; et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. *BMJ* 2019, 366, l4898. [CrossRef]

40. Sterne, J.A.; Sutton Aj Fau-Ioannidis, J.P.A.; Ioannidis Jp Fau-Terrin, N.; Terrin, N.; Fau-Jones, D.R.; Jones Dr Fau-Lau, J.; Lau, J.; Fau-Carpenter, J.; Carpenter, J.; Fau-Rücker, G.; et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. *BMJ* 2011, 343, d4002. [CrossRef]

41. Guyatt, G.H.; Oxman Ad Fau-Vist, G.E.; Vist Ge Fau-Kunz, R.; Kunz, R.; Fau-Falck-Ytter, Y; Falck-Ytter Y Fau-Alonso-Coello, P.; Alonso-Coello, P.; Fau-Schünemann, H.J.; Schünemann, H.J. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008, 336, 924. [CrossRef]

42. Brozek, J.L.; Akl Ea Fau-Jaeschke, R. Jaeschke, R.; Fau-Lang, D.M.; Lang Dm Fau-Bossuyt, P.; Bossuyt, P.; Fau-Glasziou, P.; Glasziou, P.; Fau-Helfand, M.; Helfand, M.; et al. Grading evidence of quality and strength of recommendations in clinical
practice guidelines: Part 2 of 3. The GRADE approach to grading quality of evidence about diagnostic tests and strategies. Allergy 2009, 64, 1109–1116. [CrossRef] [PubMed]

43. Schünemann, H.J.; Higgins, J.P.T.; Vist, G.E.; Glasziou, P.; Akl, E.A.; Sackett, N.; Guyatt, G.H.; on behalf of the Cochrane GRADEing Methods Group. GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations Updated October 2013: The GRADE Working Group. Available online: https://training.cochrane.org/handbook/current/chapter-14 (accessed on 9 June 2021).

44. Brandstrup, B.; Svendsen, P.E.; Rasmussen, M.; Belhage, B.; Rodt, S.; Hansen, B.; Möller, D.R.; Lundbech, L.B.; Andersen, N.; Berg, V.; et al. Which goal for fluid therapy during colorectal surgery is followed by the best outcome: Near-maximal stroke volume or zero fluid balance? Br. J. Anaesth. 2012, 109, 191–199. [CrossRef] [PubMed]

45. Calvo-Vecino, J.M.; Ripollés-Melchor, J.; Mythen, M.G.; Casans-Francès, R.; Balik, A.; Artacho, J.P.; Martínez-Hurtado, E.; Serrano Romero, A.; Fernández Pérez, C.; Asuero de Lis, S. Effect of goal-directed haemodynamic therapy on postoperative complications in low-moderate risk surgical patients: A multicentre randomised controlled trial (FEDORA trial). Br. J. Anaesth. 2018, 120, 734–744. [CrossRef] [PubMed]

46. Cho, H.J.; Huang, Y.H.; Poon, K.S.; Chen, K.B.; Liao, K.H. Perioperative hemodynamic optimization in laparoscopic sleeve gastrectomy using stroke volume variation to reduce postoperative nausea and vomiting. Surg. Obes. Relat. Dis. Off. J. Am. Soc. Bariatr. Surg. 2021, 17, 1549–1557. [CrossRef]

47. Demirel, I.; Bolat, E.; Altun, A.Y.; Ozdemir, M.; Bestas, A. Efficacy of Goal-Directed Fluid Therapy via Plèth Variability Index During Laparoscopic Roux-en-Y Gastric Bypass Surgery in Morbidly Obese Patients. Obes. Surg. 2017, 28, 358–363. [CrossRef]

48. Gómez-Izquierdo, J.C.; Trainito, A.; Mirzakandov, D.; Stein, B.L.; Liberman, S.; Charlebois, P.; Pecorelli, N.; Feldman, L.S.; Carlí, F.; Baldini, G. Goal-directed Fluid Therapy Does Not Reduce Primary Postoperative Illeus after Elective Laparoscopic Colectomy Surgery: A Randomized Controlled Trial. Anesthesiology 2017, 127, 36–49. [CrossRef]

49. Joosten, A.; Raj Lawrence, S.; Colesnicenco, A.; Coeckelenbergh, S.; Vincent, J.L.; van der Linden, P.; Cannesson, M.; Rinehart, J. Personalized Versus Protocolized Fluid Management Using Noninvasive Hemodynamic Monitoring (ClearSight System) in Patients Undergoing Moderate-Risk Abdominal Surgery. Anesth. Analg. 2019, 129, e68–e12. [CrossRef]

50. Liu, Z.; Yu, J.; Liu, Y.; Zhang, J.; Zhang, W.; Guo, F. Effect of goal-directed fluid therapy on gastrointestinal function of patients after laparoscopic radical resection of cervical cancer. Cancer Res. Clin. Oncol. 2021, 33, 204–208. [CrossRef]

51. Liu, F.; Lv, J.; Zhang, W.; Liu, Z.; Dong, L.; Wang, Y. Randomized controlled trial of regional tissue oxygenation following goal-directed fluid therapy during laparoscopic colorectal surgery. Int. J. Clin. Exp. Pathol. 2019, 12, 4390–4399.

52. Mei, X.; Liu, J.; Wang, Y.; Wei, L.; Tan, S. Application of stroke volume variation-guided liquid therapy in laparoscopic precision hepatectomy. Zhong Nan Da Xue Xue Bao Yi Xue Ban J. Cent. South Univ. Med. Sci. 2019, 44, 1163–1168. [CrossRef]

53. Muhlbacher, J.; Luf, F.; Zotti, O.; Herkner, H.; Fleischmann, E.; Kabon, B. Effect of Intraoperative Goal-Directed Fluid Management on Tissue Oxygen Tension in Obese Patients: A Randomized Controlled Trial. Obes. Surg. 2021, 31, 1129–1138. [CrossRef] [PubMed]

54. Ratti, F.; Cipriani, F.; Reineke, R.; Catena, M.; Paganelli, M.; Comotti, L.; Beretta, L.; Aldrighetti, L. Intraoperative monitoring of stroke volume variation versus central venous pressure in laparoscopic liver surgery: A randomized prospective comparative trial. HPB 2018, 16, 136–144. [CrossRef] [PubMed]

55. Senagore, A.J.; Emery, T.; Luchtefeld, M.; Kim, D.; Djuovny, N.; Hoedema, R. Fluid management for laparoscopic colorectal colectomy: A prospective, randomized assessment of goal-directed administration of balanced salt solution or hetastarch coupled with an enhanced recovery program. Dis. Colon Rectum 2009, 52, 1935–1940. [CrossRef] [PubMed]

56. Tang, A.; Zhou, S. Analysis on the application value of goal-directed fluid therapy in patients undergoing laparoscopy-assisted radical gastrectomy with fast-track anesthesia. Am. J. Transl. Res. 2021, 13, 5174–5182. [PubMed]

57. Wen, X.L.; Jing, G.X.; He, P.; Hou, J.R. Clinical study on the capacity management guided by stroke volume variation in elderly patients with laparoscopic radical gastrectomy for gastric cancer. J. Xi’an Jiaotong Univ. (Med.) 2016, 37, 851–856. [CrossRef]

58. Yin, K.; Ding, J.; Wu, Y.; Peng, M. Goal-directed fluid therapy based on noninvasive cardiac output monitor reduces postoperative complications in elderly patients after gastrointestinal surgery: A randomized controlled trial. Pak. J. Med. Sci. 2018, 34, 1320–1325. [CrossRef]

59. Nguyen, N.T.; Wolfe, B.M. The physiologic effects of pneumoperitoneum in the morbidly obese. Ann. Surg. 2005, 241, 219–226. [CrossRef]

60. Maddison, L.; Starkopf, J.; Reintam Blaser, A. Mild to moderate intra-abdominal hypertension: Does it matter? World J. Crit. Care Med. 2016, 5, 96–102. [CrossRef]

61. Saugel, B.; Vincent, J.L. Protocolised personalised peri-operative haemodynamic management. Eur. J. Anaesthesiol. 2019, 36, 551–554. [CrossRef]

62. Molnar, Z.; Benes, J.; Saugel, B. Intraoperative hypotension is just the tip of the iceberg: A call for multimodal, individualised, contextualised management of intraoperative cardiovascular dynamics. Br. J. Anaesth. 2020, 125, 419–423. [CrossRef]

63. Moore-Oluwemimi, S.D.; Xue, H.; Fau-Attuwaybi, B.O.; Attuwaybi Bo Fau-Fischer, U.; Fischer, U.; Fau-Harari, Y.; Harari, Y.; Fau-Oliver, D.H.; Oliver Dh Fau-Weisbrodt, N.; Weisbrodt, N.; et al. Resuscitation-induced gut edema and intestinal dysfunction. J. Trauma 2005, 58, 264–270. [CrossRef] [PubMed]

64. Chowdhury, A.H.; Lobo, D.N. Fluids and gastrointestinal function. Curr. Opin. Clin. Nutr. Metab. Care 2011, 14, 469–476. [CrossRef]
65. Mythen, M.G.; Webb, A.R. Perioperative plasma volume expansion reduces the incidence of gut mucosal hypoperfusion during cardiac surgery. *Arch Surg.* 1995, 130, 423–429. [CrossRef] [PubMed]

66. Myles, P.S.; Bellomo, R.; Corcoran, T.; Forbes, A.; Peyton, P.; Story, D.; Christophi, C.; Leslie, K.; McGuinness, S.; Parke, R.; et al. Restrictive versus Liberal Fluid Therapy for Major Abdominal Surgery. *N. Engl. J. Med.* 2018, 378, 2263–2274. [CrossRef]

67. Holte, K.; Kehlet, H. Fluid therapy and surgical outcomes in elective surgery: A need for reassessment in fast-track surgery. *J. Am. Coll. Surg.* 2006, 202, 971–989. [CrossRef] [PubMed]

68. Rahbari, N.N.; Zimmermann, J.B.; Schmidt, T.; Koch, M.; Weigand, M.A.; Weitz, J. Meta-analysis of standard, restrictive and supplemental fluid administration in colorectal surgery. *Br. J. Surg.* 2009, 96, 331–341. [CrossRef] [PubMed]

69. Holte, K.; Kehlet, H. Fluid therapy and surgical outcomes in elective surgery: A need for reassessment in fast-track surgery. *J. Am. Coll. Surg.* 2006, 202, 971–989. [CrossRef] [PubMed]

70. Heming, N.; Moine, P.; Coscas, R.; Annane, D. Perioperative fluid management for major elective surgery. *Br. J. Surg.* 2020, 107, e56–e62. [CrossRef] [PubMed]

71. Gan, T.J.; Soppitt, A.; Maroof, M.; el-Moalem, H.; Robertson, K.M.; Moretti, E.; Dwane, P.; Glass, P.S. Goal-directed intraoperative fluid administration reduces length of hospital stay after major surgery. *Anesthesiology* 2002, 97, 820–826. [CrossRef]

72. Grocott, M.P.W.; Dushianthan, A.; Hamilton, M.A.; Mythen, M.G.; Harrison, D.; Rowan, K.; Optimisation Systematic Review Steering Group. Perioperative increase in global blood flow to explicit defined goals and outcomes after surgery: A Cochrane Systematic Review. *Br. J. Anaesth.* 2013, 111, 535–548. [CrossRef]

73. Wakeling, H.G.; McFall, M.R.; Jenkins, C.S.; Woods, W.G.; Miles, W.F.; Barclay, G.R.; Fleming, S.C. Intraoperative oesophageal Doppler guided fluid management shortens postoperative hospital stay after major bowel surgery. *Br. J. Anaesth.* 2005, 95, 634–642. [CrossRef] [PubMed]

74. O’Malley, C.; Cunningham, A.J. Physiologic Changes during Laparoscopy. *Anesthesiol. Clin. N. Am.* 2001, 19, 1–19. [CrossRef]

75. Meregalli, A.; Oliveira Rp Fau-Friedman, G.; Friedman, G. Occult hypoperfusion is associated with increased mortality in hemodynamically stable, high-risk, surgical patients. *Crit. Care* 2004, 8, R60–R65. [CrossRef] [PubMed]

76. Forget, P.; Lois, F.; de Kock, M. Goal-directed fluid management based on the pulse oximeter-derived pleth variability index reduces lactate levels and improves fluid management. *Anesth. Analg.* 2010, 111, 910–914. [CrossRef] [PubMed]